(BRKR) Bruker - Overview
Stock: Spectrometers, Microscopes, Superconductors, Biosensors, Analyzers
| Risk 5d forecast | |
|---|---|
| Volatility | 48.1% |
| Relative Tail Risk | -5.60% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.28 |
| Alpha | -45.61 |
| Character TTM | |
|---|---|
| Beta | 1.177 |
| Beta Downside | 0.275 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.72% |
| CAGR/Max DD | -0.31 |
EPS (Earnings per Share)
Revenue
Risks
Description: BRKR Bruker March 01, 2026
Bruker Corporation (NASDAQ: BRKR) designs, manufactures and sells a broad portfolio of scientific instruments and analytical solutions across four operating segments-Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies-serving life-science, materials, and industrial markets worldwide.
In its most recent fiscal year (FY 2025), Bruker reported revenue of $2.2 billion, up 8 % year-over-year, with an operating margin of 15 % and free cash flow of $380 million, reflecting strong demand for its MALDI-TOF microbial identification platforms and high-resolution mass spectrometry systems. R&D intensity remained high at roughly 12 % of revenue, supporting continued product innovation in multi-omics and superconducting technologies. The company’s market capitalization sits near $7 billion, with the stock trading around $70 per share.
Key drivers for Bruker’s growth include accelerating global biotech R&D spending (projected to rise ~10 % annually), expanding clinical microbiology testing volumes, and a rebound in capital-equipment budgets as supply-chain constraints ease. The life-sciences tools sector also benefits from increased adoption of AI-enabled data analytics, which aligns with Bruker’s integrated data-solution offerings.
For a deeper dive into valuation metrics and peer comparison, you might explore Bruker’s profile on ValueRay.
Headlines to watch out for
- Global research and development spending impacts instrument demand
- Healthcare capital expenditure drives diagnostic solution sales
- Supply chain disruptions increase manufacturing costs
- Regulatory changes for medical devices affect product approvals
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -8.60m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.65 > 1.0 |
| NWC/Revenue: 27.16% < 20% (prev 22.93%; Δ 4.23% < -1%) |
| CFO/TA 0.02 > 3% & CFO 134.1m > Net Income -8.60m |
| Net Debt (1.74b) to EBITDA (297.2m): 5.87 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (152.5m) vs 12m ago 0.33% < -2% |
| Gross Margin: 46.62% > 18% (prev 0.49%; Δ 4.61k % > 0.5%) |
| Asset Turnover: 57.05% > 50% (prev 57.97%; Δ -0.93% > 0%) |
| Interest Coverage Ratio: 1.34 > 6 (EBITDA TTM 297.2m / Interest Expense TTM 57.2m) |
Altman Z'' 2.94
| A: 0.15 (Total Current Assets 2.21b - Total Current Liabilities 1.28b) / Total Assets 6.24b |
| B: 0.38 (Retained Earnings 2.36b / Total Assets 6.24b) |
| C: 0.01 (EBIT TTM 76.9m / Avg Total Assets 6.02b) |
| D: 0.61 (Book Value of Equity 2.28b / Total Liabilities 3.73b) |
| Altman-Z'' Score: 2.94 = A |
Beneish M -2.97
| DSRI: 1.03 (Receivables 736.0m/701.2m, Revenue 3.44b/3.37b) |
| GMI: 1.05 (GM 46.62% / 49.00%) |
| AQI: 0.99 (AQ_t 0.50 / AQ_t-1 0.51) |
| SGI: 1.02 (Revenue 3.44b / 3.37b) |
| TATA: -0.02 (NI -8.60m - CFO 134.1m) / TA 6.24b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of BRKR shares?
Over the past week, the price has changed by -4.39%, over one month by -13.25%, over three months by -20.62% and over the past year by -18.80%.
Is BRKR a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BRKR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.4 | 32.3% |
| Analysts Target Price | 48.4 | 32.3% |
BRKR Fundamental Data Overview March 10, 2026
P/S = 1.6247
P/B = 2.2729
P/EG = 1.5155
Revenue TTM = 3.44b USD
EBIT TTM = 76.9m USD
EBITDA TTM = 297.2m USD
Long Term Debt = 1.85b USD (from longTermDebt, last quarter)
Short Term Debt = 51.8m USD (from shortTermDebt, last quarter)
Debt = 2.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.74b USD (from netDebt column, last quarter)
Enterprise Value = 7.33b USD (5.58b + Debt 2.04b - CCE 298.8m)
Interest Coverage Ratio = 1.34 (Ebit TTM 76.9m / Interest Expense TTM 57.2m)
EV/FCF = 169.2x (Enterprise Value 7.33b / FCF TTM 43.3m)
FCF Yield = 0.59% (FCF TTM 43.3m / Enterprise Value 7.33b)
FCF Margin = 1.26% (FCF TTM 43.3m / Revenue TTM 3.44b)
Net Margin = -0.25% (Net Income TTM -8.60m / Revenue TTM 3.44b)
Gross Margin = 46.62% ((Revenue TTM 3.44b - Cost of Revenue TTM 1.83b) / Revenue TTM)
Gross Margin QoQ = 47.77% (prev 44.88%)
Tobins Q-Ratio = 1.17 (Enterprise Value 7.33b / Total Assets 6.24b)
Interest Expense / Debt = 0.40% (Interest Expense 8.10m / Debt 2.04b)
Taxrate = 21.0% (US default 21%)
NOPAT = 60.8m (EBIT 76.9m * (1 - 21.00%))
Current Ratio = 1.73 (Total Current Assets 2.21b / Total Current Liabilities 1.28b)
Debt / Equity = 0.83 (Debt 2.04b / totalStockholderEquity, last quarter 2.46b)
Debt / EBITDA = 5.87 (Net Debt 1.74b / EBITDA 297.2m)
Debt / FCF = 40.28 (Net Debt 1.74b / FCF TTM 43.3m)
Total Stockholder Equity = 2.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.14% (Net Income -8.60m / Total Assets 6.24b)
RoE = -0.40% (Net Income TTM -8.60m / Total Stockholder Equity 2.13b)
RoCE = 1.93% (EBIT 76.9m / Capital Employed (Equity 2.13b + L.T.Debt 1.85b))
RoIC = 1.43% (NOPAT 60.8m / Invested Capital 4.23b)
WACC = 7.59% (E(5.58b)/V(7.63b) * Re(10.25%) + D(2.04b)/V(7.63b) * Rd(0.40%) * (1-Tc(0.21)))
Discount Rate = 10.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.20%
[DCF] Terminal Value 77.52% ; FCFF base≈80.4m ; Y1≈69.9m ; Y5≈55.9m
[DCF] Fair Price = N/A (negative equity: EV 1.10b - Net Debt 1.74b = -646.1m; debt exceeds intrinsic value)
EPS Correlation: -31.53 | EPS CAGR: 5.08% | SUE: -1.01 | # QB: 0
Revenue Correlation: 88.18 | Revenue CAGR: 14.15% | SUE: 0.61 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.45 | Chg7d=+0.033 | Chg30d=+0.025 | Revisions Net=+4 | Analysts=12
EPS current Year (2026-12-31): EPS=2.12 | Chg7d=-0.017 | Chg30d=-0.011 | Revisions Net=-2 | Growth EPS=+15.9% | Growth Revenue=+4.2%
EPS next Year (2027-12-31): EPS=2.42 | Chg7d=-0.008 | Chg30d=-0.026 | Revisions Net=-5 | Growth EPS=+14.0% | Growth Revenue=+4.2%
[Analyst] Revisions Ratio: +0.50 (6 Up / 2 Down within 30d for Next Quarter)